Page 9 - Ancer Prostate News Today

But pathologists largely think the name should stay, results of a recent survey show.

Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.

For patients with metastatic castration-resistant prostate cancer, talazoparib combined with enzalutamide achieved better progression-free survival than enzalutamide alone.

For patients with metastatic castration-resistant prostate cancer with BRCA alterations, rucaparib doubled progression-free survival as compared with docetaxel, abiraterone, or enzalutamide.

"If a patient doesnt achieve remission or very low disease activity, obtaining a radiograph doesnt change what you do … youre going to make a change anyway," Dr. Roy Fleischmann said.

A tool to identify patients with psoriasis at high risk of psoriatic arthritis appears near to clinical application.

A study documents the steep financial burden of breast cancer care for women in high and low/middle income countries and offers avenues for intervention.

Medicare could save more than $1 billion each year just on urology drugs by using Mark Cubans cost-plus drug pricing model, new findings suggest.

In almost all Latin American countries, mortality decreased among individuals aged 50 years and older, but age-specific trends were not consistent.

Perhaps one of your patients could benefit from clinical trials that are currently recruiting patients with urologic cancers, including prostate cancer.